Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.
Clinical trials and studies are indexed under the acronym of the name.

AACE algorithm/guidelines for treatment, 75, 76, 78, 87, 93
Abbreviations and acronyms, 287-290
ACE inhibitors, 152
Acute pancreatitis (AP), 63-64
ADAPT (Arthritis Diet, and Activity Promotion Trial), 121-122
Adipokines, 30, 56
Adiponectin, 29
Adipose signals, 29, 30
Adipose tissue, factors secreted by, 26, 29, 30, 47, 49
Adjustable gastric banding (AGB), 253, 260-262, 261
complications and mortality, 269, 270t
diabetes and, 273, 274t
efficacy, 263-264, 265-267, 265, 266t
mechanisms of action, 261-262
potential advantages and disadvantages, 263t
Adolescents
bariatric surgery in, 273-275
prevalence of obesity in, 14-15, 273-275
Agouti-related peptide. See AgRP.
AgRP (agouti-related peptide), 24-26, 25, 34, 35
lowered satiety and overeating with, 25, 26
neurons, 24-26, 25, 27, 34, 35
stimulation of, 24-26, 25
Algorithm for treatment, 75, 76, 78, 87, 93, 141, *142-143*
α-Adrenergic blockers, 130t
Amphetamine derivatives, 183, 184t
Amylin, AgRP production and, 26
Anorexigenic substances/pathway, 26, 30, 43, 210, *246*
Anti-epileptic drugs, 149t, 152-153
Antibiotics, 39
Anticonvulsant medications, 130t, 149t, 152-153
Antidepressants, 130t, 148t, 154-156
Antidiabetic medications, 130t, 146-151, 149t
Antihistamines, 131t, 150t, 156
Antihypertensive medications, 148t-149t, 151-152
Antimanic agent, 130t
Antineoplastics, 131t
Antipsychotics, 130t, 150t, 154-156
Antiretroviral medications, 156
Apnea. See Obstructive sleep apnea.

Appetite. See also Satiety.

hypothalamic regulation of, 24-26, 32
satiety and, 26, 28
suppression, by obesity treatments, 33, 34, 35

ARBs, 152
Arcuate nucleus (ARC), 24, 25, 26, 27

Arthritis
ADAPT trial, 121-122
osteoarthritis (OA), 59
weight loss benefit for, 121-122

Autonomic nervous system, 28

Babinski-Frohlich syndrome, 42
Bacteria, 39
Bardet-Biedl syndrome, 33, 36

Bariatric surgery, 251-285
in adolescents, 273-275
BMI categories, and treatment choices, 92t, 253
candidates and qualifications, 251-253
clinical experience/efficacy, 262-269, 281
AGB, 263-264, 265-267, 265, 266t, 269, 270t
BPD/DS, 266t, 268, 269
gastroplasty, 266t
laparoscopic procedures, 263-264, 269
recent individual studies, 264-268, 266t
RYGB, 263-264, 265-267, 265, 266t, 269, 270t
safety, 268-269, 270t
complications, 268-269, 277-278
operative (30-day) mortality, 268, 269, 270t
reoperation rates, 269, 270t
systematic reviews and meta-analyses, 262-264, 265
VSG, 263, 264, 265, 267-268, 269, 270t
contraindication for pregnancy, 277
as diabetes treatment, 271-273

Bariatric surgery (continued)

future development and devices, 280-281
duodenal-jejunal bypass sleeve (EndoBarrier), 280-281
gastric electrical stimulation (GES), 280
implantable devices, 280
intensification of therapies to achieve weight loss goals, 93
mechanisms of action for weight loss, 254, 256, 281
number of procedures performed, 251, 252
obstructive sleep apnea (OSA) and, 275-277
postsurgical care, 277-278
laboratory follow-up, 279t

 procedures, 253-262
adjustable gastric banding (AGB), 253, 260-262, 261
complications and mortality, 269, 270t
diabetes and, 273, 274t
efficacy, 263-264, 265-267, 265, 266t
mechanisms of action, 261-262
potential advantages and disadvantages, 263t
biliopancreatic diversion with or without duodenal switch (BPD or BPD/DS), 254, 258-260, 259
complications and mortality, 269, 270t
diabetes and, 272-273
efficacy, 266t, 268
mechanisms of action, 258, 259-260
potential advantages and disadvantages, 260t
laparoscopic approaches, 254, 263-264
Roux-en-Y gastric bypass (RYGB), 253, 255, 264-266
complications and mortality, 269, 270t
diabetes and, 271-273, 274t
efficacy, 263-264, 265-267, 265, 266t
mechanisms of action, 256
as nonreversible, 255
potential advantages and disadvantages, 256t
sleep improvement with, 119-121
vertical sleeve gastrectomy (VSG), 254, 256-257, 257
complications and mortality, 269, 270t
diabetes and, 271-272, 274t
efficacy, 263, 264, 265-267-268
mechanisms of action, 257
potential advantages and disadvantages, 258t
questions for patients, 253
safety, 268-269, 270t

Swedish Obese Subjects (SOS) study, 278-280
Basal metabolic rate, 23
Behavioral modification, 171-172, 179, 243
Contrave Obesity Research Behavioral Modification (COR-BMOD) trial, 224-225, 226t-227t, 229-230, 231, 233
Behavioral Risk Factor Surveillance System, 50
Belviq. See Lorcaserin (Belviq).
Benzphetamine, 184t
β-Blockers, 131t, 148t, 151
Biliopancreatic diversion with or without duodenal switch (BPD or BPD/DS), 254, 258-260, 259
 complications and mortality, 269, 270t
diabetes and, 272-273
efficacy, 266t, 268
mechanisms of action, 258, 259-260
potential advantages and disadvantages, 260t
Binge-eating disorder, 41
Bioelectrical impedance analysis (BIA), 135
Bisphenol A, 37
Blood pressure (BP)
high, 53. See also Hypertension.
 improvement values with lorcaserin, 220t
 improvement with phen/top ER (Qsymia), 203-205, 206
 improvement with weight loss, 98-100, 103, 106, 107t, 109, 117
 in metabolic syndrome, 85t, 104t
BLOOM trial, 211, 213, 214t-215t, 216, 218, 220t-223t
BLOOM-DM trial, 211, 213-217, 214t-215t, 217, 218, 219, 220t-221t
BLOSSOM trial, 211-212, 212, 214t-215t, 219, 220t-221t
 secondary endpoints in, 218, 220t-221t
BMI (body mass index), 129-131
 BMI-centric model for treatment, 77-78, 87, 92t
 comorbidities and, 55t, 56, 57t
 genetics and, 38
 hypertension and, 51t
 mortality statistics and, 15-19, 16, 18t, 20-21
 obesity classification/categories, 13, 49t, 57t, 77, 82-83, 129-131, 132t
 in overweight, 13
 in severe obesity, 13
BMI (body mass index) (continued)
sleep deprivation and, 41
in treatment algorithm, 142-143
BMIQ Professionals Program, 177-178
Body fat, percentage of, 133-135, 134t
Body mass index. See BMI (body mass index).
Bupropion
 action mechanism, 33, 34, 224
 POMC and appetite suppression, 33, 34
Bupropion SR plus naltrexone SR. See Contrave (naltrexone SR/bupropion SR).
C-reactive protein (CRP), 47-50, 49t, 51t
Calcium channel blockers, 152
Cancer
 comorbid with obesity, 59-61
 EPIC study, 60-61
 mortality statistics, 18-19, 20-21
 obesity and, 18-19, 20-21
Carbamazepine, 149t, 152
Carbohydrates
 content of diet, 165-167
 low carbohydrate diets, 163, 166-167
CARDIA study, 86, 90
Cardiac valvulopathy, 184, 219
Cardiometabolic Disease Staging System (CMDS), 84-87, 88t-89t, 91
Cardiovascular disease
 mortality statistics, 18, 18t
 obesity and, 48, 53-54, 67
Cardiovascular risk factors
lorcaserin and, 220t-221t
reduction by weight loss (DPP/DPPOS), 78-79, 98-100, 102-103
reduction by weight loss (Look AHEAD), 105-114, 107t, 108-111, 116-117
topiramate and, 206-207t
CART (cocaine- and amphetamine-regulated transcript), 26
neurons, 25, 26, 27, 246
Carvedilol, 148t, 151-152
CCK (cholecystokinin), 26, 28, 29, 43
Central adiposity, 132
Central nervous system (CNS). See also Hypothalamus.
regulation and satiety signals, 32
Children, prevalence of obesity in, 14-15, 273-275
Cholecystokinin (CCK), 26, 28, 29, 43
Chronic renal failure (CRF), 66
Clinical trials, 211-212, 212, 214-215
CACurrent brain MRIs, 55
Contraceptives, hormones, and steroids, 150t, 153-154
Contrave (naltrexone SR plus bupropion SR), 33, 186t-192t, 224-238
action mechanisms, 224
adverse events, 189t, 233, 236t-237t
contraindications, 188t-189t
dosage/administration, 191t-192t, 233-238
efficacy, 224-234, 226t-227t
COR-I trial, 224-225, 226t-227t, 228, 230
COR-II trial, 224-229, 226t-227t, 229, 233
COR-BMOD trial, 224-225, 226t-227t, 229-230, 231, 233
COR-Diabetes trial, 224-225, 226t-227t, 230, 232, 233
primary endpoints (weight loss), 225-229, 226t-227t,
228-229, 231-232
secondary endpoints (metabolic and cardiovascular risk), 230-233, 234t-235t
indications for, 186t
limitations of, 187t
prescribing information, 186t-192t, 233-238
safety, 233, 236t-237t
warnings and precautions, 190t
Contrave Obesity Research I (COR-I) trial, 224-225, 226t-227t, 228, 230
Contrave Obesity Research II (COR-II) trial, 224-229, 226t-227t, 229, 233
Contrave Obesity Research Behavioral Modification (COR-BMOD) trial, 224-225, 226t-227t, 229-230, 233
Contrave Obesity Research-Diabetes (COR-Diabetes) trial, 224-225, 226t-227t, 230, 232, 233
Coronary heart disease (CHD), 48, 53-54
Corticosteroids, 150t, 154
Cushing’s Syndrome, 40
Depression, 61-62
comorbid with obesity, 61-62
major depressive disorder (MDD), 61
weight loss, benefit of, 114-115, 118
Dexfenfluramine, 183-184, 184t
Diabetes, 50-53
AACE algorithm for treatment of, 75
antidiabetic medications, 146-151, 149t
antidiabetics medications, weight gain and, 130t
Diabetes (continued)
bariatric surgery and, 271-273, 274t, 280
CARDIA study, 86, 90
comorbid with obesity, 50-53, 51t, 52, 55t
COR-Diabetes trial (Contrave), 224-225, 226t-227t, 230, 232, 233
CRP and fibrinogen in, 47, 51t
depression and (Look AHEAD trial), 114-115, 118
DPP (Diabetes Prevention Program) Study, 95-103, 172-173, 174t
DPPOS (Diabetes Prevention Program Outcomes Study), 95-103
DPP and DPPOS, 95-103
metabolic syndrome in, 101-103, 104t
objectives and design, 95-97
prevention/delay of diabetes, 97-98, 97, 99, 99t
reduction in CV risk factors, 98-100, 102-103
weight loss in severely obese patients, 100-101
Look AHEAD trial, 78-79, 105-122, 173, 174t
objectives and design, 105
reduction in CV events and risk factors, 105-114, 107t, 108-111, 116-117
reduction of depression, 114-115, 118
remission of diabetes, 112, 113
prediction of, 86, 88t-89t, 90
SCALE Diabetes trial (liraglutide), 239-241, 240t
type 2, 50, 52, 271-273
Diarrhea, liraglutide and, 243, 244t
Diet, 161-169, 179, 243
behavioral modification and, 171-172
BMI categories, and treatment choices, 92t
cognitive restructuring and, 172
composition relative to cardiometabolic parameters, 166-168
low calories diets (LCDs), 163, 163t
low carbohydrate diets, 163, 166-167
low energy density diets, 164
low fat diets, 166-167
macronutrient content, comparison of, 165-166
magnitude of weight loss, 161
meal replacements, 164-165
new options in, 91
Diet (continued)
portion size and, 169
problem-solving techniques and, 171-172
protein-sparing modified fast (PSMF), 162-163
relapse prevention, 172
sample dietary compositions, 163t
self-monitoring of intake, 171
tips for counseling patients on, 168, 168, 169
trigger or stimulus control, 171
very low calories diets (VLCDs), 161-162, 163
Diethylpropion, 184t
Disease staging. See Staging of obesity.
Dizziness
naltrexone SR/bupropion SR and, 233, 236t
phentermine and, 193-194
phentermine/topiramate ER (phen/top) and, 208
Dopamine, 34
reward pathway, 31
DPP-4 inhibitors, 147, 149t
DPP (Diabetes Prevention Program) study, 95-103, 172-173, 174t
metabolic syndrome in, 101-103, 104t
objectives and design, 95-97
prevention/delay of diabetes, 97-98, 97, 99, 99t
reduction in CV risk factors, 98-100, 102-103
weight loss in severely obese patients, 100-101
DPPOS (Diabetes Prevention Program Outcomes Study), 95-103. See also DPP (Diabetes Prevention Program) study.
Drug-induced weight gain, 145-160. See also Medications; Weight gain.
Dry mouth
lorcaserin and, 218, 222t
naltrexone SR/bupropion SR and, 233, 236t
phentermine and, 193-194
phentermine/topiramate ER (phen/top) and, 208
Duodenal-jejunal bypass sleeve (EndoBarrier), 280-281
DXA (formerly DEXA), 133-135
Dyslipidemia, 53-54, 55t, 80, 85t
improvement with weight loss, 98-100, 102, 106-112, 107t, 110-111, 116-117
in metabolic syndrome, 104t
Edmonton Obesity Staging System (EOSS), 79-80, 81t, 82-83
EndoBarrier (duodenal-jejunal bypass sleeve), 280-281
Endocrine disruptors, 37
Energy balance (homeostasis), 23-26, 32, 43
basal metabolic rate, 23
basic mechanisms of, 23-24
changes in, associated with weight loss, 42-43
hypothalamus and, 23-26, 25, 27, 29
peptide modulators of, 27
positive energy balance, 32
regulation of, 23-43
resting energy expenditure (REE), 42
total energy expenditure (TEE), 23, 42-43
Environmental chemicals, 37
Environmental factors, 37-38
vs genetics, 38
EPIC (European Prospective Investigation into Cancer and Nutrition), 60-61
Epigenetics, 37
EQUIP trial, 197-198, 200t-201t, 202, 206t-207t
Etiology. See Pathophysiology of obesity.
European Prospective Investigation into Cancer and Nutrition (EPIC), 60-61
Evaluation
examination of patient, 129-136
risk assessment, and disease staging, 79-87
of weight-related comorbidities, 137-139
weight-specific history, 127-129
Examination of patient, 129-136
Exercise. See Physical activity.
Fasting glucose, 82, 85t, 104t
improved values with lorcaserin, 220t
improved values with phen/top ER (Qsymia), 203-205, 205, 207
Fat
amount in diet, 166
low fat diets, 166-167
storage, 24
Fenfluramine, 183-184, 184t
Fetus, obese mothers and, 37
Fibrinogen, 47-50, 49t
Food, rewarding effect of, 31, 32
Food intake, 23-26, 43. See also Diet; Energy balance.
homeostatic control of, 23-24
hypothalamus and, 23-26, 25, 27, 29
peptide modulators of, 27
regulation of, 23-26, 25, 27, 29, 32
reward circuitry and, 31, 32
FTO gene (fat mass and obesity associated gene), 33, 36
Gallbladder disease, 62-63
Gastrectomy. See Vertical sleeve gastrectomy (VSG).
Gastric banding. See Adjustable gastric banding (AGB).
Gastric bypass. See Roux-en-Y gastric bypass (RYGB).
Gastric distention, 28
Gastric electrical stimulation (GES), 280
Gastric emptying, delayed, 28
Gastrointestinal signaling, 28-30, 29
Gender
mortality rates and, 16, 18-19, 20-21
prevalence of obesity and, 13-15, 14
Genetic factors, 33-38
epigenetics, 37
gene mutations, 33-36
obesity genes, 33-36
twin studies, 38
vs environment, 38
Ghrelin, 26, 27, 29
actions of, 28-30
AgRP production and, 24
antagonist (in development), 246
increased with weight loss, 43
GLP-1. See Glucagon-like peptide.
Glucagon-like peptide (GLP-1), 28, 29, 147, 149t
liraglutide, 238-243
potential new therapeutic targets, 246
Growth hormone deficiency, 40
Gut hormones, 26, 28-30, 29
Gut microbes, 38-39
Gynecological abnormalities, 48
Hazard ratios (HR), 15-18, 16
Headaches, naltrexone SR/bupropion SR and, 233, 236t
Hedonic pathway, 31, 32, 43
High blood pressure (BP), 53
History, weight-specific, 127-129
HIV, medications for, 156
Homeostasis, 23-24. See also Energy balance.
Hormone replacement therapy (HRT), 154
Hormones, 26-30, 29
Humoral signaling, 28-30, 29
humoral factors, 26-28
Hyperphagia
leptin deficiency and, 30
POMC deficiency and, 36
Hypertension, 53, 55t
antihypertensive medications, 148t-149t, 151-152
CRP and fibrinogen in, 47, 51t
improvement with weight loss, 98-100, 103, 106, 107t, 109, 117
Hypothalamic obesity (HO), 41-42
Hypothalamus, 24-26
damage to and syndromes of, 41-42
genetic defects, 33
potential new therapeutic targets, 246
as regulator of energy balance and food intake, 23-26, 25, 27, 29, 32
Hypothyroidism, 40
Hypoventilation syndromes, 137
Inflammation, 47-50
Insomnia, phentermine/topiramate ER (phen/top), 208
Insulin, 26, 27, 29, 30
AgRP production and, 26
fasting levels of, 30
reduced levels with weight loss, 43
resistance, 80
weight gain and, 146-147, 149t
Jenny Craig, 175
Kidneys, chronic renal failure (CRF), 66
Laboratory examination, 136-137
Leptin, 26, 27, 29, 30
AgRP production and, 26
deficiency/absence of, 30, 33-36
gene mutations, 33-36
reduced levels with weight loss, 43
Lifestyle interventions, 172-179, 174t, 243-245
BMIQ Professionals Program, 177-178
commercially available, 175-176
Jenny Craig, 175
NutriSystem, 175-176
Weight Watchers, 175
intensification of therapies to achieve weight loss goals, 93
intensive, in DPP and DPPOS, 95-103, 172-173, 174t
key components, 179
long-term intervention, necessity of, 179
magnitude of weight loss, 179
remote and mobile technologies, 176-177
Limitations of, 187t, limitations of, 187t
Lipids
dyslipidemia, 53-54, 55t, 80, 85t
improved values with lorcaserin, 218, 220t
improved values with phen/top ER (Qsymia), 203-205, 206
improved values with weight loss, 98-100, 102, 106-112, 107t, 110-111, 116-117
in metabolic syndrome, 104t
Liraglutide (Saxenda), 184-185, 186t-192t, 238-243
adverse effects, 189t
adverse events, 243, 244t-245t
approved treatments, 238
brand names: Saxenda and Victoza, 238
contraindications, 188t-189t
dosage/administration, 191t
efficacy, 238-243
SCALE Diabetes, 239-241, 240t
SCALE Maintenance, 241-243, 242
SCALE Obesity and pre-diabetes, 239, 240t
elimination half-life, 238
indications for, 186t
limitations of, 187t
safety, 243, 244t-245t
Liraglutide (Saxenda) (continued)
  side effects, 189t
  warnings and precautions, 190t
Liver, nonalcoholic fatty liver disease (NAFLD), 64
Look AHEAD trial, 78-79, 100-101, 105-122, 173, 174t
  magnitude of weight loss, clinical benefits and, 112-114, 116-117
  objectives and design, 105
  reduction in CV events and risk factors, 105-112, 107t, 108-111
  reduction of depression, 114-115, 118
  reduction of obstructive sleep apnea, 115-121, 120
  remission of diabetes, 112, 113
Lorcaserin (Belviq), 184, 185, 210-233
  action mechanism, 33, 35, 210-211, 246
  adverse effects, 189t, 218-219, 222t-223t
  approval of, 90, 210
  cautions, 219
  clinical trials, 211-217, 214t-215t
    BLOOM, 211, 213, 214t-215t, 216, 218, 219, 220t-221t
    BLOOM-DM, 211, 213-217, 214t-215t, 217, 218, 219, 220t-221t
    BLOSSOM, 211-212, 212, 214t-215t, 218, 219, 220t-221t
  secondary endpoints, 218, 220t-221t
  contraindications, 188t, 188t-189t
  dosage/administration, 191t, 219
  efficacy, 211-217
  enhancement of POMC by, 33, 35
  indications for, 186t
    indications for discontinuance, 219
    limitations of, 187t
    prescribing and administration, 219
    safety, 218-219, 222t-223t
  as Schedule IV controlled substance, 191t, 219
  side effects, 189t, 218-219, 222t-223t
  warnings and precautions, 190t
Low calories diets (LCDs), 163, 163t
Low carbohydrate diets, 163, 166-167
Low energy density diets, 164
Low fat diets, 166-167
Macronutrient content (of diet), 165-166
Management of obesity. See Treatment of obesity.
MCH1R antagonist, 246
Meal replacements, 164-165
Medical conditions (linked to obesity), 39-41
  binge-eating disorder, 41
  Cushing’s Syndrome, 40
  growth hormone deficiency, 40
  hypothyroidism, 40
  night-eating syndrome, 41
  PCOS, 40
  sleep deprivation, 41
Medical model, 87-91
Medications contributing to obesity/weight gain, 39, 129, 130t-131t, 145-160
  anticonvulsant medications, 149t, 152-153
  antidiabetic medications, 146-151, 149t
  antihistamines, 150t, 156
  antihypertensive medications, 148t-149t, 151-152
  antipsychotics and antidepressants, 148t, 150t, 154-156
  contraceptives, hormones, and steroids, 150t, 153-154
  HIV medications/antiretrovirals, 156
  weight-neutral medications, 148t-150t
Megestrol acetate, 150t, 153
Melanocortin receptor 4 (MC4R), 26, 33, 34, 35, 246
Melanocyte-stimulating hormone (α-MSH), 26, 33
Men
  mortality statistics, 16, 18-19, 20-21
  prevalence of obesity in, 13-15, 14
Metabolic factors, 28, 49
Metabolic syndrome, 80-84
  abnormal findings in, 84, 85t, 104t
  diagnostic criteria for, 84, 85t
  prevalence of, 54, 55t
  weight loss, benefits of, 101-103, 104t
“Metabolically healthy obesity (MHO),” 67
Metformin, 147, 149t
Metreleptin, 246
Monoamine oxidase inhibitors, 130t, 148t, 155
Mortality, 15-19
all-cause, 15-17, 16
BMI and, 15-19, 16, 18t, 20-21, 77-78
cancer-related, 18-19, 20-21
cardiovascular-related, 86, 91
cause-specific, 17-19, 18t
hazard ratios, 15-18, 16
metabolic syndrome and, 84
obesity-associated, 15-19, 67, 75-77
prediction of, with EOSS or BMI criteria, 82-83
risk, reduction with weight loss, 78-79
Mutations, genetic, 33-36
Naltrexone, action mechanism, 33, 34, 224, 246
Naltrexone SR/bupropion SR (Contrave), 186t-192t, 224-238
action mechanisms, 224
adverse events, 189t, 233, 236t-237t
contraindications, 188t-189t
dosage/administration, 191t-192t, 233-238
efficacy, 224-234, 226t-227t
COR-I trial, 224-225, 226t-227t, 228, 230
COR-II trial, 224-229, 226t-227t, 229, 233
COR-BMOD trial, 224-225, 226t-227t, 229-230, 231, 233
COR-Diabetes trial, 224-225, 226t-227t, 230, 232, 233
primary endpoints (weight loss), 225-229, 226t-227t,
  228-229, 231-232
secondary endpoints (metabolic and cardiovascular risk),
  230-233, 234t-235t
FDA approval of, 90, 184, 185
indications for, 186t
limitations of, 187t
prescribing information, 186t-192t, 233-238
safety, 233, 236t-237t
warnings and precautions, 190t
National Health and Nutrition Examination Study.
See NHANES.
Nausea
liraglutide and, 243, 244t
lorcaserin and, 218, 222t
naltrexone SR/bupropion SR and, 233, 236t
Neuropeptide Y (NPY), 24, 25, 34, 35
neurons, 24-26, 25, 27, 34, 35, 246

NHANES (National Health and Nutrition Examination Study), 47, 49t
body weight and diabetes in, 50, 52
EOSS and, 80, 82-83
metabolic syndrome, 54, 55t
mortality statistics, 86, 91
Night-eating syndrome, 41
Nonalcoholic fatty liver disease (NAFLD), 48, 64
Nucleus accumbens (NAc), 31, 32
Nurses’ Health Study, 50
NutriSystem, 175-176

Obese patient. See Patient (obese patient).
Obesity. See also Severe obesity:
as a chronic disease, xii, 23, 75, 144, 245
classes of, 49t, 57t
comorbidities of, 47-74
defined by BMI, 13, 49t, 77, 132t
focus on risk reduction, 77-78
“metabolically healthy,” 67
mortality statistics, 15-19, 67
pathophysiology of, 23-46
prevalence of, 13-15, 14
staging systems, 79-87, 139-140
treatment of, 75-285
Obstructive sleep apnea (OSA), 56-58
bariatric surgery and, 275-277
weight loss benefit for, 115-121, 120
Older adults, prevalence of obesity in, 13-14
Oral contraceptives, 150t, 153-154
Orexigenic substances/pathway, 24, 28, 30, 43, 246
Orlistat (Xenical), 184t, 185, 194-196
adverse effects, 189t
contraindications, 188t
dosage/administration, 191t, 195-196
efficacy, 194-195, 195
formulations and dosages available (Xenical and Alli), 196
indications for, 186t, 194
limitations of, 187t
prescribing information, 186t-192t, 195-196
safety/adverse events, 195
side effects, 189t
Osteoarthritis (OA), 59, 121-122
ADAPT trial, 121-122
comorbid with obesity, 59
weight loss benefit for, 121-122
Overweight
BMI in, 13, 17, 49t, 132t
mortality and, 17-18
OXM (oxyntomodulin), 29

Pancreas, factors secreted by, 26, 27, 30
Pancreatitis, 48, 63-64
Paresthesia, phen/top and, 208
Pathophysiology of obesity, 23-46
adaptive responses to weight loss, 42-43
ergy balance and food intake regulation, 23-26
genetic and environmental factors, 33-38
gut microbes, 38-39
humoral signaling, 26-30
hypothalamic obesity (HO), 41-42
hypothalamus, 24-26
medical conditions, 39-41
obesity pharmacotherapy and, 33
peripheral signaling, 26-28
regulation of food intake, 23-26, 25, 27, 29, 32
reward/hedonic pathway, 31, 32
Patient (obese patient), 127-144
approach to, 127-144
body fat, percentage of, 133-135, 134t
examination, 129-136
goal setting, 140
laboratory examination, 136-137
motivation, assessment of, 140
office equipment, 140-141
physical examination, 136
review of medications, 129, 130t-131t
treatment plan, creating, 141-144, 142-143
weight-specific history, 127-129
disease staging and risk assessment, 139-140
medical model and, 87-91
treatment plan, creating, 141-144
PCOS (polycystic ovary syndrome), 40, 65-66
comorbid with obesity, 65-66
Peptide YY (PYY), 28, 29, 43
Peptides, 27, 29
AgRP (agouti-related peptide), 24-26, 25, 34, 35
glucagon-like peptide (GLP-1), 28, 29
neuropeptide Y (NPY), 24, 25, 34, 35
peptide YY (PYY), 28, 29, 43
Peripheral signaling, 26-28
potential new therapeutic targets, 246
Pharmacologic treatment, 183-249, 186t-192t. See also specific medications.
adverse events. See specific drugs.
amphetamine derivatives, 183-184, 184t
BMI categories, and treatment choices, 92t
bupropion, 33, 34
emerging antiobesity agents, 243, 246
history of weight loss drugs, 183-184
intensification of therapies to achieve weight loss goals, 93
medications available prior to 2012, 183-184, 184t
medications withdrawn, 184, 184t
medications causing weight gain, 39, 129, 130t-131t, 145-160
treatment selection to prevent weight-gain, 145-146
medications currently available, 184-185, 186t-192t.
See also specific medications.
liraglutide (Saxenda), 185, 238-243
lorcaserin (Belviq), 33, 184, 210-223
naltrexone SR/bupropion SR (Contrave), 184, 185, 224-238
orlistat (Xenical), 185, 194-196
phentermine, 183-184, 184t, 185-194, 193
phentermine and topiramate ER (phen/top ER; Qsymia), 184, 185, 196-210
naltrexone, 33, 34
new drug approval process, 183
new options in, 90, 184, 243, 246
pathways targeted, 33, 34, 35, 246
bupropion, 33, 34, 224
Contrave (naltrexone SR/bupropion SR), 33, 224
lorcaserin, 33, 35
naltrexone, 33, 34, 224
for treatments in development, 246
treatment selection to prevent weight-gain, 145-146
Phen/top. See Phentermine/topiramate ER (Qsymia).
Phendimetrazine, 184t
Phentermine, 184t, 185-194, 186t-192t
  action mechanism, 33, 185, 246
  adverse effects, 189t
  contraindications, 188t-189t
  dosage/administration, 191t, 194
  efficacy, 185-193, 193
  fixed dose combination with topiramate ER, 184, 186t-192t
  indications for, 186t, 194
  limitations of, 187t
  prescribing and information, 186t-192t, 194
  safety/adverse events, 193-194
  as schedule IV controlled substance, 191t, 194
  side effects, 189t
  warnings and precautions, 190t
Phentermine/topiramate ER (Qsymia), 184, 185, 196-210
  action mechanism, 196, 246
  adverse events, 189t, 205-210, 206t-207t, 209t
  contraindications, 188t-189t
  dosage/administration, 191t-192t, 210
  efficacy
    CONQUER, 198-199, 201t, 203, 205, 206t-207t, 208
    EQUIP, 197-198, 200t-201t, 202, 206t-207t
    long-term, 199-202
    secondary endpoints, 203-205, 206t-207t
    SEQUEL study, 206t-207t, 208
  indications for, 186t, 196
  limitations of, 187t
  prescribing information, 186t-192t, 210
  safety, 205-210
  as Schedule IV controlled substance, 191t, 210
  side effects, 189t
  warnings and precautions, 190t, 205
Phlebitis, 48
Physical activity, 170-171, 179
  BMI categories, and treatment choices, 92t
  in DPP and DPPOS, 96
Physical examination, 136
Pioglitazone, 147, 149t
Polycystic ovary syndrome. See PCOS.
POMC (proopiomelanocortin), 26, 34, 35
deficiency of, 36
  enhancement by bupropion and naltrexone, 33, 34, 224
  enhancement by lorcaserin, 33, 35
  enhancement by phentermine, 33
gen, 33
  neurons, 25, 26, 27, 34, 35
  potential new therapies targeting, 246
Portion size, 169
Prader-Willi syndrome, 33, 36
Pramlintide, 246
Prescription medications. See Pharmacologic treatment.
Prevalence
  of comorbidities with obesity, 50-55
  of obesity, 13-15, 14
Primary care physicians, 127
Problem-solving techniques, 171-172
Progestins, 150t, 153
Proopiomelanocortin. See POMC.
Protease inhibitors, 156
Protein
  content of diet, 165-166
  protein-sparing modified fast, 162-163
Protein-sparing modified fast (PSMF), 162-163
Psychiatric conditions (linked to obesity), 39, 139
Pulmonary disease, 48
Qsymia. See Phentermine/topiramate ER (Qsymia).
Regulation of food intake, 23-26, 25, 27, 29, 32
Resting energy expenditure (REE), 42
Reward (hedonic) pathway, 31, 32, 43
Rimonabant, 184t
Risk
  assessment, 79-87, 90, 139-140
  reduction, focus on, 77-78
Rosiglitazone, 147, 149t
Roux-en-Y gastric bypass (RYGB), 253, 255, 264-266
  complications and mortality, 269, 270t
  diabetes and, 271-273, 274t
  efficacy, 263-264, 265-267, 265, 266t
  mechanisms of action, 256
Roux-en-Y gastric bypass (RYGB) (continued)
as nonreversible, 255
potential advantages and disadvantages, 256
sleep improvement with, 119-121

Satiety
biochemical signals for, 26, 28-30, 29, 32
decreased, following weight loss, 43
Saxenda. See Liraglutide.
Selective serotonin inhibitors (SSRIs), 130t, 148t, 155
SEQUEL, 199-202, 201t, 206t-207t
Serotonin (5-HT), 28, 35
AgRP production and, 26
releasing agents (fenfluramine and dexfenfluramine), 183-184
Severe obesity
BMI in, 13, 132t
prevalence of, 13
weight loss in (Look AHEAD trial), 100-101
SGLT2 (sodium glucose cotransporter 2), 149t, 151
Sibutramine, 184t
Signals
adipose, 29, 30
gastrointestinal, 28-30, 29
humoral, 28-30, 29
pancreatic, 26, 27, 30
peripheral, 26-28
Sinusitis, phen/top and, 208
Sleep, 41
apnea, 56-58, 115-121
STOP-BANG Questionnaire, 137, 138
deprivation, 41
obstructive sleep apnea (OSA), 56-58
bariatric surgery and, 275-277
weight loss benefit for, 115-121, 120
problems, with phentermine, 193-194
Sleep AHEAD study, 115-121, 120
Social environment, 37-38
Sodium glucose cotransporter 2 (SGLT2), 149t, 151
SQUEL study, 208
SSRIs (selective serotonin inhibitors), 130t
Staging of obesity, 79-84, 139-140
BMI criteria and, 82-83
Cardiometabolic Disease Staging System (CMDS), 84-87,
88t-89t, 91
Edmonton Obesity Staging System (EOSS), 79-80, 81t,
82-83
metabolic syndrome and, 80-84
Steroids, 130t, 150t, 154
Stimulus control, 171
STOP-BANG Questionnaire, 137, 138
Sulfonylureas, 146, 149t
Surgery. See Bariatric surgery.
Swedish Obese Subjects (SOS) study, 278-280
Thermogenesis, 23
Thiazolidinediones (TZDs), 146-147, 149t
Thyroid, hypothyroidism, 40
TNF-α. See Tumor necrosis factor alpha.
Topiramate. See Phentermine/topiramate ER.
Total energy expenditure (TEE), 23
reduction in, with weight loss, 42-43
Treatment of obesity, 75-285. See also specific topics.
algorithm for treatment, 75, 76, 78, 87, 93, 141, 142-143
approach to obese patient, 127-144
bariatric surgery, 251-285
behavioral modification, 171-172, 179
BMI-centric (weight loss) model, 77-78, 87, 92t
complications-centric approach, 75-94
evaluation, risk assessment, and disease staging, 79-87,
90
focus on risk reduction, 77-78
intensification of therapies, 93
medical model, 87-91
obesity as a disease, 75-77, 87
weight loss reduction of comorbidity and mortality risk,
78-79
diet, 161-169, 179
goals for, 78, 87
intensification of therapies, 93
lifestyle interventions, 172-179
medical model, 87-91
medications inducing weight gain, 145-160
Treatment of obesity (continued)
multidisciplinary/multimodal approach, 243-245
new options for, 87-91
pharmacologic treatment, 183-249. See also
  Pharmacologic treatment; specific medications.
medications available prior to 2012, 183-184, 184t
medications currently available, 184-185, 186t-192t
  liraglutide (Saxenda), 185, 238-243
  lorcaserin (Belviq), 33, 184, 210-223
  naltrexone SR/bupropion SR (Contrave), 184, 185, 224-238
  orlistat (Xenical), 185, 194-196
  phentermine, 183-184, 184t, 185-194, 193
  phentermine and topiramate ER (phen/top ER; Qsymia), 184, 185, 196-210
  new options in, 90, 184, 246
physical activity, 170-171, 179
plan, creating, 141-144, 142-143
risk reduction as treatment goal, 77-78, 87
team approach in, 141
treatment plan, creating, 141-144
weight gain, drug-induced, 145-160
weight loss, 78-79, 95-125
Tricyclic antidepressants, 130t, 148t, 155
Trigger control, 171
Tumor necrosis factor alpha (TNF-α), 26-28
Twin studies, 38
Type 2 diabetes, 50, 52. See also Diabetes.

Underweight, BMI in, 132t

Vagal stimulation, 28
Valproic acid, 149t, 152
Valvulopathy, 184, 219
Vertical sleeve gastrectomy (VSG), 254, 256-257, 257
  complications and mortality, 269, 270t
  diabetes and, 271-272, 274t
  efficacy, 263, 264, 265, 267-268
  mechanisms of action, 257
  potential advantages and disadvantages, 258t
Very low calories diets (VLCDs), 161-162, 163
Visceral fat, 132

Waist circumference, 131-133
Waist-hip ratio, 131-133
Weight categories, BMI and, 13, 49t
Weight gain. See also Drug-induced weight gain.
diabetes risk and, 50, 52
drug-induced, 145-160
medications causing, 129, 130t-131t, 145-160, 148t-150t
anticonvulsant medications, 149t, 152-153
antidiabetic medications, 146-151, 149t
antihistamines, 150t, 156
antihypertensive medications, 148t-149t, 151-152
antipsychotics and antidepressants, 148t, 150t, 154-156
contraceptives, hormones, and steroids, 150t, 153-154
HIV medications/antiretrovirals, 156
metabolic changes after weight loss and, 43
regain after diets, 161, 162
treatment selection to prevent weight-gain, 145-146
Weight loss, 95-125
benefits of, 95-125
  improvement for osteoarthritis, 121-122
  metabolic syndrome, incidence and resolution of, 101-103, 104t
  reduction of cardiovascular risk, 90-100, 102-103, 105-112, 107t, 108-111
  reduction of comorbidities, 78-79
  reduction of depression, 114-115, 118
  reduction of diabetes risk, 50-53
  reduction of mortality risk, 78-79
  reduction of obstructive sleep apnea, 115-121, 120
  remission of diabetes, 112, 113
  in severely obese patients, 100-101
commercially available programs, 175-176
  Jenny Craig, 175
  NutriSystem, 175-176
  Weight Watchers, 175
diet and, 161-169
DPP and DPPOS studies, 95-103, 172-173, 174t
increased drive to eat associated with, 43
intensification of therapies to achieve weight loss goals, 93
lifestyle interventions for, 172-179
Look AHEAD Study, 100-101, 105-122, 173, 174t
magnitude of, and clinical benefits, 112-114, 116-117
Weight loss (continued)
medications associated with, 148t-150t
medications for, 183-249, 186t-192t
medications, reduction or substitution of, 129
reduced energy expenditure associated with, 42-43
remote and mobile technologies, 176-177
responses to, 42-43
as therapeutic intervention, 78
as treatment goal, 78
Weight-neutral medications, 148t-150t
Weight Watchers, 175
Women
  mortality statistics, 16, 18-19, 20-21
  prevalence of obesity in, 13-15, 14

Xenical. See Orlistat (Xenical).